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The neurotrophins are a family of secreted 
growth factors consisting of nerve growth fac-
tor, brain-derived neurotrophic factor (BDNF), 
NT3 (neurotrophin 3), and NT4. Although 
initially described in the nervous system, they 
regulate processes such as cell survival, prolifer-
ation, and differentiation in several other com-
partments, e.g., the immune and the muscular 
system (Berzi et al., 2008; Colombo et al., 
2011a,b). Normally secreted by neurons and 
glia cells, the neurotrophins exert a wide range 
of functions important for the development 
and maintenance of the vertebrate nervous sys-
tem, as they control neuronal differentiation 
and survival and modulate synaptic structure 
and plasticity (Reichardt, 2006; Cohen and 
Greenberg, 2008). Neurotrophin signaling is 
mediated by the p75NTR receptor, which is a 
member of the tumor necrosis factor receptor 
superfamily, by the tyrosine kinase (TK) Trk 
membrane receptors, or by p75NTR-Trk 
receptor heterodimers. Truncated Trk isoforms 
lacking the TK domain occur in nature and can 
signal after ligand binding (Baxter et al., 1997; 
Rose et al., 2003; Ohira et al., 2005).
Astrocytes can express neurotrophin recep-
tors (Wang et al., 1998), but the outcome of 
neurotrophin signaling in this cell type is still 
unclear. Astrocytes endow neurons with trophic 
and metabolic support and regulate dendritic 
growth and axon guidance (Blackburn et al., 
2009). They promptly react to central nervous 
system (CNS) insults by forming the scar tissue 
(Sofroniew, 2009), and dysregulation of their ac-
tivity can have detrimental effects on CNS func-
tion. Although activated astrocytes can support 
neuroprotection, e.g., by release of neurotrophic 
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Neurotrophin growth factors support neuronal survival and function. In this study, we show 
that the expression of the neurotrophin receptor TrkB is induced on astrocytes in white 
matter lesions in multiple sclerosis (MS) patients and mice with experimental autoimmune 
encephalomyelitis (EAE). Surprisingly, mice lacking TrkB specifically in astrocytes were 
protected from EAE-induced neurodegeneration. In an in vitro assay, astrocytes stimulated 
with the TrkB agonist brain-derived neurotrophic factor (BDNF) released nitric oxide (NO), 
and conditioned medium from activated astrocytes had detrimental effects on the mor-
phology and survival of neurons. This neurodegenerative process was amplified by NO 
produced by neurons. NO synthesis in the central nervous system during EAE depended on 
astrocyte TrkB. Together, these findings suggest that TrkB expression on astrocytes may 
represent a new target for neuroprotective therapies in MS.
© 2012 Colombo et al. This article is distributed under the terms of an 
Attribution–Noncommercial–Share Alike–No Mirror Sites license for the first six months 
after the publication date (see http://www.rupress.org/terms). After six months 
it is available under a Creative Commons License (Attribution–Noncommercial– 
Share Alike 3.0 Unported license, as described at http://creativecommons.org/ 
licenses/by-nc-sa/3.0/).
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To analyze the contribution of astrocyte TrkB to neu-
roinflammation, we performed EAE experiments in dou-
ble transgenic mice, in which TrkB was excised specifically 
in GFAP-positive cells (GFAP-cre:TrkBflox/flox mice; Luikart 
et al., 2005). Cre recombination in the spinal cord of trans-
genic mice was efficient (Fig. 2, A–D), as indicated by the 
staining for the reporter gene -gal and by the lack of TrkB 
on astrocytes in naive (Fig. 2 A) and EAE (Fig. 2 B) animals. 
TrkB depletion was specific to astrocytes, as other cell types 
such as infiltrating immune cells expressed the neurotrophin 
receptor (Fig. 2 B, right). GFAP levels in naive and EAE 
KO animals were comparable with those in control litter-
mates (not depicted), indicating that expression of hGFAP-cre 
does not exert detectable toxic effects on the formation 
of white matter astrocytes. Likewise, EAE expression in 
hGFAP-cre single transgenic mice is comparable with that 
in wild-type animals (Haroon et al., 2011). Quantification of 
TrkB-T1 signal on astrocytes confirmed the up-regulation 
in control EAE animals and the lack of expression in dou-
ble transgenic animals (Fig. 2 D). Compared with control 
TrkBflox/flox littermates, conditional KO mice showed 
ameliorated disease (Fig. 2, E and F), which did not result 
from abnormal primary immune responses, as the in vitro 
proliferation rate to MOG35–55 peptide of both spleen and 
lymph node cells was similar in immunized KO and control 
mice (Fig. 2 G). Histopathological experiments showed that 
immune cell infiltration was almost halved (208 ± 18 vs. 
386 ± 4 cells/mm2; P < 0.01; Fig. 3 A) in the spinal cord of 
KO mice compared with control littermates. Characteriza-
tion of inflammatory infiltrates indicated 50–70% reduc-
tion in CD4 T lymphocytes, B cells, and macrophages in 
GFAP-cre:TrkBflox/flox mice (Fig. 3, B–D). 
However, a more dramatic effect was seen 
on neurodegeneration, as it was >90% reduced 
(6 ± 2 vs. 123 ± 12 Alzheimer precursor 
protein [APP]–positive cells/mm2 in KO vs. 
control EAE mice; P < 0.05; Fig. 3 E). Inter-
estingly, in conditional KO mice, there were 
very few degenerating axons despite inflam-
mation (Fig. 3 F). These experiments indicate 
a detrimental role for astrocyte TrkB in 
neuroinflammation and, most significantly, 
in neurodegeneration.
factors (Stadelmann et al., 2002), they also participate in in-
flammatory reactions, producing cytokines and chemokines 
(Farina et al., 2007; Cordiglieri and Farina, 2010).
In the present study, we report the marked up-regulation 
of the TrkB receptor on astrocytes in experimental autoim-
mune encephalomyelitis (EAE) and multiple sclerosis (MS) 
lesions. Importantly, transgenic animals lacking astrocyte 
TrkB were protected from the neurodegeneration associated 
with EAE. So we explored in vitro the effects of neurotroph-
ins on astrocyte–neuron interactions using live imaging tech-
niques. Surprisingly, soluble factors released by astrocytes as a 
result of TrkB signaling induced neuronal degeneration and 
apoptosis. Finally, we identified nitric oxide (NO) as the key 
neurotoxic molecule released from activated astrocytes after 
TrkB engagement in vitro and in vivo.
RESULTS
Depletion of astrocyte TrkB protects mice  
from EAE and neurodegeneration
After EAE induction with myelin oligodendrocyte glycopro-
tein (MOG)35–55 peptide, C57BL/6 mice showed a marked 
increase in TrkB expression in inflamed white matter of the 
spinal cord compared with naive mice (Fig. 1, A and B). 
Double immunofluorescence and confocal imaging demon-
strated that astrocytes (positively stained for glial fibrillary 
acidic protein [GFAP]) strongly up-regulated TrkB in im-
munized animals (Fig. 1, C and D). Staining with an anti-
body directed to the truncated TrkB isoform commonly 
expressed in glial cells (Rose et al., 2003; Ohira et al., 2005; 
Dorsey et al., 2006) confirmed massive TrkB-T1 expression 
in astrocytes in EAE animals (Fig. 1, E and F).
Figure . EAE lesions are characterized by en-
hanced astrocyte TrkB. (A and B) Immunohistochemis-
try for TrkB (brown staining, DAB; counterstaining, 
hematoxylin) in naive (A) and EAE (B) mouse spinal cord. 
(C–F) Double immunofluorescence for GFAP and the ECD 
of TrkB (TrkB-ECD in C and D) or the isoform TrkB-T1 
(E and F) in naive (C and E) and EAE (D and F) mice. DAPI 
was used to stain for nuclei. Representative stainings of 
two naive mice and four EAE mice from two independent 
EAE experiments are shown. Inset at higher magnifica-
tion (100× objective, one z plane) shows colocalization. 
Bars, 50 µm.
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Figure . Double transgenic mice lacking TrkB in GFAP+ cells are protected from EAE. (A) TrkB depletion in astrocytes in GFAP-cre:TrkBflox/
flox mice. Immunohistochemistry for -galactosidase (-Gal; left), GFAP (middle), and TrkB (right) in the spinal cord of TrkBflox/flox (top) and GFAP- 
 cre:TrkBflox/flox (bottom) naive mice (brown staining with DAB and hematoxylin counterstaining). (B) Immunohistochemistry for GFAP (left) and TrkB (middle) 
and double immunofluorescence (right) in the spinal cord of GFAP-cre:TrkBflox/flox EAE mice. DAPI was used to stain for nuclei. Arrows indicate TrkB-
positive immune cells. (A and B) The antibody directed to the ECD of TrkB (Cell Signaling Technology) was used. Bars, 50 µm. (C) Quantification of TrkB-T1 
immunoreactivity in spinal cord white matter of naive and EAE mice. AU, arbitrary units. (D) Colocalization between TrkB-T1 and GFAP in naive and EAE 
mice. Data are given as mean percentage of GFAP signal. (C and D) Four mice/group from two independent EAE experiments and two naive mice/group 
were analyzed. Error bars represent SEM. (E) EAE disease course. Clinical expression of MOG35–55-induced EAE in GFAP-cre:TrkBflox/flox mice (n = 13) com-
pared with TrkBflox/flox control littermates (n = 20). P-value lines refer to significant differences over time. Error bars indicate SEM. (F) Table summarizing 
EAE clinical parameters in GFAP-cre:TrkBflox/flox mice and control littermates. Data from three EAE experiments were pooled, analyzed, and given as 
mean ± SEM. Only diseased animals were included in the analysis for the onset, max score, score at peak, and cumulative disease index (C.D.I.). p.i., 
postimmunization. (G) Proliferation of draining lymph node (drLNs; top) or spleen (bottom) cells of GFAP-cre:TrkBflox/flox (n = 5) and TrkBflox/flox (n = 5) 
mice at day 10 after immunization with MOG35–55 peptide, as assessed by [3H]thymidine incorporation. Values are expressed as percentage of unstimu-
lated control cells. Similar observations were obtained in a second experiment. Error bars indicate SEM. *, P < 0.05; **, P < 0.01; ***, P < 0.001.
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Figure . GFAP-cre:TrkBflox/flox mice are protected from EAE-associated neurodegeneration. (A–D) Inflammation at peak of disease.  
(A) Images show hematoxylin and DAPI stainings of the spinal cord (S.C.) of GFAP-cre:TrkBflox/flox (right) and TrkBflox/flox mice (left) at day 18 after 
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BDNF-activated astrocytes induce fast  
neuronal degeneration
To study the effects of TrkB ligation on glia–neuronal inter-
actions, we developed an in vitro model system with human 
primary fetal astrocytes and rat primary neurons. Astrocytes 
were treated for 4 h with BDNF or the inflammatory stimu-
lus IL1. Medium was then changed to remove recombinant 
factors, and supernatants were collected after a further 24 h 
in culture. This astrocyte-conditioned medium (ACM) was 
then incubated with the neurons.
First, we performed live imaging of cultures exposed to 
ACM for 20 h. Neurons showed no morphological changes 
when exposed to supernatants from nontreated astrocytes 
(sNT; Fig. 5 A, Fig. S1, and Video 1). Conversely, superna-
tants from IL1-treated astrocytes (sIL1) triggered a rapid de-
generative response in neurons (Fig. 5 A, Fig. S1, and Video 2). 
These cultures showed budding of vesicles, fragmentation, 
retraction, and thinning of extensions, similarly to what has 
been described in vivo during degeneration (Kerschensteiner 
et al., 2005; Trapp and Stys, 2009). Within a few hours, neu-
ronal processes were disrupted, and rounded-up cell bodies 
showed signs of nuclear condensation. Surprisingly, a very 
similar phenomenon was observed when neurons were ex-
posed to supernatants from BDNF-treated astrocytes (sBDNF; 
Fig. 5 A, Fig. S1, and Video 3). Imaging of neuronal cultures 
exposed to recombinant BDNF did not show significant 
neurodegeneration until 20-h incubation (rBDNF; Fig. 5 A 
and Video 4). Overall, these observations indicate that astro-
cytic responses to BDNF may accelerate neurodegenera-
tive processes.
As live-imaging fields contained limited numbers of cells, 
we further quantified this phenomenon in larger areas of 
neuronal cultures. Instead of phase-contrast images, -tubulin 
staining was used to better define neuronal bodies and pro-
cesses (Melli et al., 2006b). A clear drop in -tubulin mean 
fluorescence intensity (MFI) was observed in sBDNF cultures 
(Fig. 5, B and C), which was significant at low BDNF concen-
trations (1–5 ng/ml) and comparable with sIL1 cultures 
(Fig. 5 C, first panel). Conversely, the same amount of 
BDNF was unable to trigger degeneration when given di-
rectly to neurons (rBDNF; Fig. 5 D, first panel). Both the per-
centage of cells with neurites and neurite length decreased to 
similar extents in neuronal cultures incubated with sIL1 or 
sBDNF (Fig. 5 C, second and third panels), whereas rBDNF 
induced only minor effects at 25 ng/ml (Fig. 5 D). Finally, 
Human astrocytes up-regulate the TrkB  
receptor in MS lesions
We used immunohistochemistry with an antibody directed 
against the TrkB extracellular domain (ECD) on 14 normal 
control brain white matter samples and 12 chronic inactive MS 
lesions. Although localized on occasional cells with astrocyte-
like morphology in normal control brain (Fig. 4 A, first 
panel), the neurotrophin receptor was strongly expressed in 
MS lesions (Fig. 4 B, first panel). Confocal microscopy 
showed that TrkB labeled a few GFAP-positive astrocytes in 
control white matter (Fig. 4 A, second panel). Similarly to 
the inflamed white matter of MOG35–55 immunized mice, in 
MS lesions, TrkB was expressed on the network of astrocytic 
processes (Fig. 4 B, second panel).
In addition to the human full-length TrkB, two intracel-
lularly truncated isoforms, TrkB-T1 and TrkB-Shc, have been 
described previously (Stoilov et al., 2002). We examined 
their transcript levels by quantitative PCR on human brain 
cDNA samples. TrkB-T1 was the most abundant isoform in 
controls and was significantly up-regulated in MS lesions, 
whereas TrkB-TK and TrkB-Shc were barely detectable 
(Fig. 4 C). MS tissue samples were stained with antibodies 
specific for either the full-length (TrkB-TK) receptor or the 
truncated TrkB-T1 isoform. Although full-length TrkB was 
localized exclusively on some axons in both normal control 
tissues and MS lesions (Fig. 4, A and B, fourth panels), TrkB-T1 
was present on astrocytes in control brain tissue (Fig. 4 A, 
third panel) and strongly up-regulated on these cells in MS 
lesions (Fig. 4 B, third panel). In contrast, the p75NTR neuro-
trophin receptor was undetectable on astrocytes both in 
control and MS brain samples (Fig. 4, A and B, fifth panels). 
This observation was confirmed by immunofluorescence 
experiments with three distinct anti-p75NTR monoclonal anti-
bodies (see Materials and methods) and is in agreement with 
other published data on human CNS specimens (Dowling 
et al., 1999; Holley et al., 2003; Petratos et al., 2004). In par-
allel to our in vivo observations, quantitative PCR experi-
ments showed that truncated TrkB-T1 levels in cultured 
human astrocytes far exceeded those of the two other iso-
forms (Fig. 4 D). Flow cytometry for TrkB-ECD confirmed 
surface expression of the receptor on the majority of cultured 
astrocytes (Fig. 4 E), which were also positive for TrkB-T1 
(Fig. 4 F) but not TrkB-TK (not depicted). Thus, human astro-
cytes preferentially express the truncated isoform of the neuro-
trophin receptor, which is up-regulated in MS lesions.
immunization with MOG35–55 peptide. Graphic plots show quantification of white matter inflammation in different regions of the spinal cord in GFAP-cre:
TrkBflox/flox mice and control littermates. The infiltration rate in the ventral white matter of the mouse spinal cord was calculated as the ratio in the 
number of DAPI+ nuclei between EAE mice and naive mice per unit of area. (B–D) Immunofluorescence for CD4, CD19, or F4/80 in GFAP-cre:TrkBflox/flox 
(right) and control mouse (left) spinal cord. Graphic plots show relative quantification. Red lines represent mean values for each group. Each dot repre-
sents an individual mouse. (E) Neurodegeneration at peak of disease. Confocal images show APP deposition in spinal cord white matter in GFAP-cre: 
TrkBflox/flox mice (right) and TrkBflox/flox control littermates (left), evaluated at day 18 after immunization. Relative quantification is given in the graphs. 
(A and E) Error bars indicate SEM. (F) Neurodegeneration versus infiltration rate in GFAP-cre:TrkBflox/flox mice and TrkBflox/flox control littermates. Four 
mice/group from two independent EAE experiments were analyzed. Bars, 50 µm. One z-stack images. *, P < 0.05; **, P < 0.01.
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signaling. To clarify this issue, first of all, we performed 
blocking experiments with a specific anti-p75NTR anti-
body (Wong et al., 2002; Colombo et al., 2011b). As shown 
in Fig. 5 G, astrocyte stimulation with BDNF in the presence 
of the blocking anti-p75NTR antibody induced disruption 
of the neuronal network and apoptosis to the same extent as 
control cultures. Second, we isolated and cultured astrocytes 
from GFAP-cre:TrkBflox/flox and control TrkBflox/flox mice. 
As expected, TrkB transcript was expressed in wild-type (2.4 ± 
0.73% of the housekeeping gene GAPDH) but not KO as-
trocytes (0%). Immunofluorescence confirmed TrkB protein 
depletion in astrocytes (Fig. 6 A). Furthermore, both cultures 
did not show p75NTR expression (0% of the housekeeping 
gene). Similarly to the experiments with human astrocytes, 
exposure of mouse wild-type astrocytes to BDNF and IL1 
led to the release of soluble factors, which induced -tubulin 
loss and apoptosis (Fig. 6 B, black bars). Importantly, KO 
both sBDNF and sIL1 supernatants induced massive apop-
tosis as detected by TUNEL (Tdt-mediated dUTP-biotin 
nick end labeling) staining (Fig. 5 C). Apoptosis was also trig-
gered directly by the recombinant factors (Fig. 5 D), although 
less efficiently than by supernatants from activated astrocytes. 
Thus, both IL1 and BDNF induced neurodegeneration and 
apoptosis directly, but astrocytic activation via the same fac-
tors strongly amplified these pathogenic processes through fast-
acting soluble factors. Interestingly, similarly to BDNF, the 
neurotrophins NT3 and NT4 could also activate the astro-
cytes and induce neurodegeneration and apoptosis (Fig. 5 E).
Responses to neurotrophins may be mediated by the Trk 
receptors and/or by the neurotrophin receptor p75NTR 
(Huang and Reichardt, 2003). Flow cytometry showed low 
p75NTR expression on a small fraction of cultured astro-
cytes (Fig. 5 F), raising the possibility that the in vitro ob-
servations were dependent on p75NTR rather than TrkB 
Figure . TrkB is expressed by human astrocytes in vivo and in vitro and up-regulated in MS lesions. (A and B) TrkB and p75NTR protein  
expression in normal control white matter (A) or MS chronic inactive lesions (B). Left panels show immunostainings with an antibody directed to the 
TrkB-ECD. In the first column, immunohistochemistry demonstrates brown DAB staining on astrocyte-like cells. Double immunofluorescence and confocal 
imaging for TrkB-ECD and GFAP are shown in the second column. Insets depict single stainings. Third and fourth columns show immunostainings for TrkB 
isoforms: TrkB-T1 isoform (brown DAB staining) in the third column and full-length TrkB (TrkB-TK) in the fourth column. The fifth column shows the ab-
sence of p75NTR immunoreactivity in GFAP-positive astrocytes. Representative stainings are shown. DAPI was used to stain for nuclei. (C and D) Quanti-
tative PCR assessment of messenger RNA (mRNA) transcripts encoding full-length TrkB-TK and the truncated T1 or Shc isoforms in normal control white 
matter (control) and MS lesions (MS; C) and in human primary astrocytes (D). Data are expressed as the percentage of the housekeeping gene PPIA. Red 
lines represent mean values for each group. Error bars indicate SD. *, P < 0.05. (E) Cytofluorimetric analysis of TrkB surface expression in human cultured 
astrocytes. (F) Confocal microscopy for TrkB-T1 isoform, GFAP, and DAPI in cultured astrocytes. Bars, 50 µm.
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Figure 5. Astrocyte responses to neurotrophins induce neurite fragmentation and neuronal death and do not require p5NTR. (A) Kinetics of 
changes in neuronal morphology after exposure to ACM as monitored by live imaging. Stimuli (IL1 or BDNF) or vehicle was given to astrocytes for 4 h and 
then removed. Cells received fresh medium and were cultured for a further 24 h. Then the ACM was collected and added to cultured neurons. Neurons 
were incubated with supernatants from nontreated (sNT), IL1-treated (10 ng/ml; sIL1), or BDNF-treated astrocytes (5 ng/ml; sBDNF) or to direct recombi-
nant BDNF (5 ng/ml; rBDNF). Neuronal network was calculated as color density in the image field, and changes over time were visualized as the percent-
age of time point 0. Five videos were analyzed per treatment at four time points. (B) Fluorescence images showing representative stainings for -tubulin, 
DAPI, and TUNEL in neuronal cultures after 24-h exposure to ACM. Bars, 50 µm. (C) Quantification of -tubulin MFI, number of cells with neurites, length 
of neurites, and percentage of apoptotic cells in neuronal cultures exposed to ACM. Changes in -tubulin MFI were calculated as the percentage of MFI in 
control cultures exposed to ACM from nontreated (sNT) astrocytes. Data were obtained in at least three independent experiments. (D) The same param-
eters as in C in neuronal cultures treated with recombinant BDNF (rBDNF) or IL1 (rIL1). Data were obtained in three independent experiments. (E) Astro-
cytes were treated with 5 ng/ml BDNF, NT-3, NT-4, or 10 ng/ml IL1. Neuronal cultures were exposed to ACM, and -tubulin MFI and the percentage of 
apoptotic cells were evaluated. Data were obtained in three independent experiments. (F) Cytofluorimetric analysis of p75NTR surface expression on  
human cultured astrocytes. (G) 25 ng/ml BDNF or vehicle was given to astrocytes for 4 h in the presence of p75NTR blocking antibody or isotype control 
and then removed. Cells received fresh medium and were cultured for a further 24 h. Then the ACM was collected and added to cultured neurons. Graphs 
show quantification of -tubulin MFI and the percentage of apoptotic cells. Three independent experiments were performed. All data are represented as 
mean ± SEM. ns, not significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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any fluorescence (Fig. 8 A and Video 5), BDNF- or IL1-treated 
astrocytes started producing NO during the first stimulation 
hour (Videos 6 and 7, respectively, and Fig. 8 A). Quantifica-
tion of fixed samples after 1.5 h revealed that 50% of astro-
cytes produced NO upon treatment with 5 ng/ml BDNF 
(Fig. 8 B). NO formation was TrkB dependent, as astrocytes 
from GFAP-cre:TrkBflox/flox mice did not produce NO 
in response to BDNF (Fig. 8 C, gray bars), whereas wild-type 
astrocytes (Fig. 8 C, black bars) did it at levels similar to 
human astrocytes (Fig. 8 B). When an NO synthase inhibitor, 
l-nitroarginine methyl ester (L-NAME), was added to human 
cultures together with stimuli, astrocytes produced much less 
NO (Fig. 8 D). Second, we tested whether the stable NO 
breakdown products (nitrites and nitrates) were present in 
astrocyte supernatants and found that BDNF and IL1 could 
indeed induce NO release from astrocytes (Fig. 8 E). Third, 
to prove the neurotoxic role of astrocytic NO, we incubated 
neurons with ACM from cells treated with L-NAME and 
then examined -tubulin expression and apoptosis. When 
generated in the presence of L-NAME, sBDNF supernatants 
caused no disruption of neuronal processes and limited cell 
apoptosis (Fig. 8, F and G). Fourth, we blocked NO produc-
tion in neurons by L-NAME and exposed them to ACM. 
This treatment hampered neurodegeneration and reduced the 
percentage of apoptotic cells (Fig. 8, H and I), demonstrating 
that neuronal NO, although triggered by BDNF-induced as-
trocytic NO, amplifies the process. Fifth, nitrotyrosine-positive 
neurons were detected in sBDNF or sIL1 cultures (Fig. 9 A), 
clearly indicating the NO-dependent posttranslational nitro-
sylation of intracellular proteins.
Finally, we examined NO synthesis and nitrosylation 
in vivo. Experimental neuroinflammation is characterized 
by peroxynitrite production in the CNS (Cross et al., 1997). 
Consistently, TrkBflox/flox EAE mice displayed strong 
immunoreactivity for the inducible NO synthase (iNOS), 
and astrocytes greatly contributed to iNOS expression as 
astrocytes induced neurodegeneration in response to IL1 but 
not to BDNF (Fig. 6 B, gray bars). We can conclude that 
astrocyte TrkB and not p75NTR mediates responses to neu-
rotrophins that trigger neurodegeneration.
Neurodegeneration is initiated by NO synthesis  
and released by astrocytes in response to BDNF  
and sustained by secondary neuronal NO boosts
As direct administration of recombinant BDNF at high 
doses induced neurodegeneration (Fig. 5 E), we wondered 
whether the effects mediated by the supernatants were 
caused by BDNF released by astrocytes. Neuronal cultures 
strongly expressed the p75NTR receptor but not TrkB 
(Fig. 7 A), indicating that responses to neurotrophins in 
neurons and in astrocytes were depending in our system 
on distinct receptors. We measured human BDNF levels 
in astrocyte supernatants by ELISA; however, they were 
<20 pg/ml at the ACM dilution given to the neuronal cul-
tures (not depicted). We further checked the potential 
involvement of astrocyte-derived BDNF in neurodegeneration 
by blocking experiments with a specific anti-BDNF anti-
body. As expected, when given to astrocytes (Fig. 7 B, gray 
bars), the blocking antibody inhibited both network disrup-
tion and apoptosis induced by sBDNF but not sIL1. In con-
trast, administration of the blocking antibody to the neuronal 
cultures together with sBDNF did not hinder the neurode-
generative process (Fig. 7 C), as -tubulin loss and apoptosis 
were comparable with control cultures. These experiments 
clearly demonstrate that astrocytic BDNF is not the media-
tor driving neurodegeneration.
As neuronal degeneration may be triggered by NO (Brown 
and Bal-Price, 2003; Pacher et al., 2007) and astrocytes may 
produce it, we investigated NO involvement in the in vitro 
model system. First, astrocytes were loaded with the fluorescent 
NO indicator DAF-FM, stimulated with BDNF, and observed 
over 4 h by live imaging. Although resting cells did not develop 
Figure . Neurodegeneration induced by astrocyte responses to BDNF depends on astrocyte TrkB. (A) Double immunofluorescence for TrkB and 
GFAP in mouse cultured astrocytes. DAPI was used to stain for nuclei. Bars, 20 µm. (B) Assay performed as in Fig. 5 on mouse astrocytes. Graphs show 
quantification of -tubulin MFI and the percentage of apoptotic cells in neuronal cultures exposed to ACM from GFAP-cre:TrkBflox/flox and TrkBflox/flox 
astrocytes treated as indicated. Data were obtained in three independent experiments and are represented as mean ± SEM. Statistics refer to comparisons 
with relative sNT (nontreated). *, P < 0.05; ***, P < 0.001; ****, P < 0.0001.
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DISCUSSION
In this paper, we addressed the role of the neurotrophin 
receptor TrkB in white matter pathology. TrkB transcripts 
are up-regulated in normal-appearing MS white matter 
(Graumann et al., 2003) and in chronic MS lesions (Mycko 
et al., 2004); however, their cellular sources have not been 
identified. We observed robust expression of TrkB on astro-
cytes in both EAE and MS lesions. Similarly, TrkB is en-
hanced in astrocytes in injured white matter (Frisén et al., 
1993; Widenfalk et al., 2001) and after neoplastic transforma-
tion (Wang et al., 1998), suggesting a link between astrocyte 
activation and TrkB up-regulation. We demonstrated in our 
quantitative PCR experiments on human cerebral tissue that 
there was marked up-regulation of the truncated isoform 
TrkB-T1 in MS tissue compared with control white matter, 
which was confirmed at the protein level by immunohisto-
chemistry with a specific antibody directed to the noncata-
lytically active isoform. TrkB-T1 was up-regulated on 
astrocytes in EAE lesions as well. During mouse develop-
ment, the expression of TrkB isoforms is tightly regulated in 
the CNS (Allendoerfer et al., 1994), and, interestingly, the 
shift from the full-length to the truncated isoform correlates 
with the onset of neuronal death and maturation of axonal 
connections (Allendoerfer et al., 1994; Ohira et al., 1999). A 
few studies demonstrate that dysregulation of TrkB isoforms 
in neurons may lead to cell death (Dorsey et al., 2002, 2006). 
In contrast, astrocytes express only truncated TrkB receptors 
(Rose et al., 2003; Ohira et al., 2005; Dorsey et al., 2006).
Although bearing a very short cytoplasmic domain, astro-
cyte TrkB mediates responses to BDNF, such as calcium 
release (Rose et al., 2003) and cytoskeletal rearrangements 
(Ohira et al., 2005). Initially we had decided to analyze the 
role of astrocyte TrkB in vivo in experimental neuroin-
flammation. Surprisingly, conditional mice lacking TrkB on 
GFAP-positive cells showed strong impairment in EAE sus-
ceptibility and severity. Histological analyses indicated that 
immune infiltrates were present in the spinal cord white matter 
of the EAE KO mice, although significantly less than in 
control EAE littermates. Moreover, neurodegeneration was 
almost absent in KO mice. Overall, our observations indicating 
that the TrkB-dependent astrocytosis supports neuroinflam-
mation and, more strongly, neurodegeneration are in contrast 
with the well-established neurotrophic functions of TrkB 
ligands. For example, BDNF has a pivotal role in the develop-
ment of the fetal and postnatal brain, and conventional BDNF 
KO mice die at birth (Korte et al., 1995). BDNF is also critical 
for the neurogenesis and the synaptic plasticity (Binder and 
Scharfman, 2004) as well as for the regeneration of neurons and 
axons after injury (Huang and Reichardt, 2003). BDNF is pro-
duced by resident CNS cells, but under inflammatory settings 
such as in MS, it may be also released by infiltrating immune 
cells (Stadelmann et al., 2002). Interestingly, BDNF produc-
tion by peripheral immune cells of MS patients is enhanced 
upon immunomodulatory therapy (Azoulay et al., 2005, 2008, 
2009; Sarchielli et al., 2007). Endogenous and immune cell–
derived BDNF can regulate experimental neuroinflammation. 
shown by the abundant iNOS signal in GFAP-positive 
cells (Fig. 9 B). In contrast, GFAP-cre:TrkBflox/flox EAE 
mice displayed a dramatic reduction in iNOS expression, 
which remained confined to some infiltrating immune 
cells (Fig. 9 B). Similarly, tyrosine nitrosylation was signif-
icantly impaired in GFAP-cre:TrkBflox/flox EAE mice but 
was strongly detected in control EAE mice (Fig. 9 C). Par-
allel analysis of human brain tissue samples showed that, al-
though absent in normal control white matter (not depicted), 
nitrosylation was detected in MS lesions (Fig. 9 D). Inter-
estingly, we observed nitrotyrosine-positive axons sur-
rounded by and in contact with the TrkB-positive gliotic 
network (Fig. 9 D).
Figure . Astrocyte BDNF is not the mediator triggering neuro-
degeneration. (A) Double immunofluorescence for p75NTR or TrkB and  
-tubulin in rat primary neurons. Bars, 50 µm. (B and C) Assay performed 
as in Fig. 5, but BDNF-neutralizing or isotype antibody was added to astro-
cyte cultures (B) or to neuronal cultures exposed to BDNF (C). In B, stimuli 
(10 ng/ml IL1 or 25 ng/ml BDNF) or vehicle was given to astrocytes in the 
presence of BDNF blocking antibody or isotype control for 4 h and  
then removed. After 24 h, the ACM was collected and added to cultured 
neurons. In C, astrocytes were treated with stimuli for 4 h. After 24 h, 
ACM was given to cultured neurons together with BDNF blocking anti-
body or isotype control. Graphs show quantification of -tubulin MFI and 
the percentage of apoptotic cells. All data were obtained in at least two 
independent experiments and are represented as mean ± SEM. If not indi-
cated, statistics refer to comparisons with relative sNT (nontreated).  
ns, not significant. *, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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transgenic animals suggest that alterations in the availability 
of BDNF may influence experimental neuroinflammation; 
however, they do not allow the dissection of the responses of 
distinct cell types to the neurotrophin. Moreover, our in vitro 
data show that, similarly to BDNF, the TrkB ligands NT3 and 
NT4 also activated the astrocytes so that neurodegeneration 
was induced, indicating multiple options for TrkB activation 
in astrocytes.
Transgenic mice with BDNF depletion in either astrocytes or 
immune cells show enhanced disease severity associated with 
axonal loss (Linker et al., 2010), suggesting a BDNF-mediated 
neuroprotective mechanism. However, neurotrophins have a 
Janus-like nature as they may also induce neuronal death 
in vitro (Friedman, 2000), and heterozygous BDNF/+ mice, 
which display half-normal BDNF levels, show ameliorated 
EAE (Javeri et al., 2010). These observations in BDNF 
Figure . TrkB-dependent NO production by astrocytes in response to BDNF triggers neurodegeneration in vitro. (A) Human primary astro-
cytes loaded with NO dye DAF-FM were stimulated with 5 ng/ml BDNF or 10 ng/ml IL1 or left nontreated (NT). NO-positive cells (green) were counted. 
Representative fields are shown. (B) Quantification of experiments described in A. The number of NO-producing cells is expressed as percent of total 
DAPI+ cells. (C) Quantification as in B of NO production by nontreated or BDNF-treated astrocytes of TrkBflox/flox and GFAP-cre:TrkBflox/flox mice.  
(D) NO production in human astrocytes was evaluated as in A and B with the addition of the NO synthase inhibitor L-NAME, where indicated.  
(E) Analysis of total nitrite/nitrate concentration in human astrocyte supernatants after 24 h of the indicated treatment. (F–I) Assay was performed as 
in Fig. 5. L-NAME was added to astrocytes (F and G) or neurons (H and I). Representative stainings for -tubulin, DAPI, and TUNEL in neuronal cul-
tures (F and H) and quantification of -tubulin MFI and apoptosis (G and I). Changes in -tubulin MFI were calculated as the percentage of MFI in 
control cultures exposed to ACM from nontreated (sNT) astrocytes. A concentration of 25 ng/ml BDNF was used in F–I to induce maximal astrocyte 
activation. Data are shown as mean ± SEM of three (B, C, G, and I) or two (D and E) independent experiments. Bars, 50 µm. ns, not significant.  
*, P < 0.05; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001.
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and apoptosis took place under both 
conditions, and NO was the common 
mediator released by astrocytes in re-
sponse to both BDNF and IL1. These 
effects were dependent on astrocyte 
TrkB, as astrocytes from GFAP-cre:
TrkBflox/flox mice did not produce 
NO and induce neuronal death. Fur-
thermore, we demonstrated that the 
fast kinetics of the neurodegenerative 
phenomenon, highlighted by the time-
lapse imaging experiments, was driven 
by the release of astrocyte NO and 
amplified by neuronal NO. NO plays 
homeostatic, physiological functions 
in the CNS, including modulation of 
neurotransmission, neuroinflammation, 
and neuroprotection (Calabrese et al., 2007). Basal NO 
levels are generated by nNOS and eNOS, which are Ca2+/
Calmodulin-dependent isoforms of NO synthases expressed 
by neurons, astrocytes, and endothelial cells (Calabrese et al., 
2007). Nitrosative stress has been well documented in several 
neurodegenerative disorders. Here, NO is produced in excess 
after activation of iNOS. Importantly, iNOS up-regulation 
takes place in astrocytes in MS (Liu et al., 2001; Jack et al., 
2007) and EAE (Cross et al., 1997) lesions. A marker of 
nitrosative stress is the nitrosylation of proteins at the level of 
tyrosine residues. We confirmed iNOS up-regulation and 
deposition of nitrotyrosine in vivo in the spinal cord of con-
trol EAE mice. Consistent with the in vitro data obtained 
from TrkB-deficient astrocytes (Fig. 8 C), both iNOS and 
Astrocytes are important regulators of neuroinflammation 
and neurodegeneration. Published data show that NF-B 
signaling in astrocytes promotes neurotoxicity and CNS in-
flammation (Brambilla et al., 2009a,b; Dvoriantchikova et al., 
2009; Fu et al., 2010). In this study, we describe for the first 
time that, as in a typical inflammatory pathway, the astrocytic 
response toward neurotrophins supports EAE expression by 
fostering a permissive environment for immune cell infiltra-
tion and neurodegeneration.
To study astrocyte–neuron interaction, we developed 
an in vitro model in which spinal neurons were exposed 
to ACM generated under BDNF stimulation and compared 
them with media generated under IL1 stimulation, which leads 
to NF-B activation. Disruption of the neuronal network 
Figure . Tyrosine nitrosylation is de-
tectable in vitro and in vivo and strongly 
reduced in GFAP-cre:TrkBflox/flox EAE 
mice. (A) Stainings for nitrotyrosine, -tubulin, 
and DAPI in neuronal cultures exposed to 
ACM from nontreated (NT; left) and BDNF 
(middle)- or IL1-treated (right) astrocytes. 
(B and C) iNOS and nitrotyrosine expression  
in EAE mice. Double immunofluorescence for 
GFAP and iNOS (B) or nitrotyrosine (C) in  
spinal cord of TrkBflox/flox and GFAP-cre:
TrkBflox/flox mice at day 18 after immunization 
with MOG35–55 peptide. Insets show enlarged 
images of iNOS- or nitrotyrosine-positive 
astrocytes. Graphs show relative quantifica-
tion. Four mice/group from two independent 
EAE experiments were analyzed. Red lines 
indicate mean values for each group. *, P < 
0.05. (D) Protein nitrotyrosilation in MS le-
sions. (left) Double immunofluorescence and 
confocal microscopy for TrkB-ECD and nitro-
tyrosine. (right) Nitrotyrosine localization on 
GFAP- or -tubulin–positive cells. Represen-
tative images of three analyzed MS lesions; 
one z-stack images. Bars: (A and D) 10 µm; 
(B and C) 50 µm.
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(aged 37–79 yr) were obtained postmortem and conserved as snap-frozen 
tissue blocks at the NeuroResource tissue bank, University College London 
Institute of Neurology (London, England, UK). Tissue collection for 
research purposes was authorized by the London Multi-Center Ethics com-
mittee (London, England, UK) and was performed after obtaining the 
informed consent form signed by a relative or appointed representative of 
the deceased donor. Both normal control white matter samples and MS 
chronic inactive plaques were from temporal, parietal, and occipital ventric-
ular or subventricular regions.
Immunohistochemistry and immunofluorescence. 10-µm-thick serial 
sections were cut from human snap-frozen CNS tissue blocks or from 4% 
paraformaldehyde (PFA)–perfused mouse spinal cords of four GFAP-cre:
TrkBflox/flox and four TrkBflox/flox mice derived from two independent 
EAE experiments at day 18 after MOG35–55 peptide immunization. At least 
seven cervical, four thoracic, and three lumbar spinal cord sections were 
labeled for each mouse. Immunohistochemistry and immunofluorescence 
were performed as previously described (Berzi et al., 2008). The following 
antibodies were used: mouse –TrkB-ECD (clone 72509; R&D Systems), 
rabbit -TrkB full length (TK; Santa Cruz Biotechnology, Inc.), rabbit 
-TrkB truncated (T1; Santa Cruz Biotechnology, Inc.), rabbit -TrkB 
(Cell Signaling Technology), rat -TrkB (L30-1; Santa Cruz Biotechnol-
ogy, Inc.), mouse -GFAP (clone 556327; BD), rabbit -GFAP (Dako), rat 
-GFAP (EMD), mouse -p75NTR (clone 74902; R&D Systems), mouse 
-p75NTR (clone NGFR5; Invitrogen), mouse -p75NTR (clone C40-1457; 
BD), rabbit -p75NTR (Millipore), mouse –-tubulin (Covance), rabbit 
-Nitrotyrosine, mouse -APP, mouse -CNPase, rabbit –-galactosi-
dase (all from Millipore), rat -CD4, rat -CD19, rat -F4/80 (all from 
eBioscience), and rabbit -iNOS (BD). As negative controls, mouse IgG1 
(Sigma-Aldrich), rat IgG1 (BioLegend), or polyclonal rabbit Igs (Dako) were 
used at the same concentration as the primary antibodies. As secondary anti-
bodies, horseradish peroxidase–labeled anti–mouse or anti–rabbit Ig (Envi-
sion system; Dako), followed by diaminobenzidine (DAB; Dako) reaction 
were used for immunohistochemistry, and Alexa Fluor 488–, Alexa Fluor 
594–, or Alexa Fluor 633–conjugated donkey or goat -mouse, -rabbit, or 
-rat IgGs (all from Invitrogen) were used for immunofluorescence. Prelim-
inary experiments have been performed to determine the optimal antibody 
concentration, which gave negative controls but clear cell-associated positive 
stainings. Immunohistochemistry sections were counterstained with hema-
toxylin, and images were acquired using a light microscope (Axiophot; Carl 
Zeiss) equipped with 20× (NA 0.50) and 40× (NA 0.75) air objectives. 
Fluorescence images were captured with confocal laser-scanning microscopes 
equipped with 40× (NA 1.30) and 60× (NA 1.40) oil objectives (D-Eclipse 
C1; Nikon) or equipped with 40× (NA 1.25) and 63× (NA 1.20) oil objec-
tives (TCS SP5; Leica). ImageProPlus 6.0 (Media Cybernetics) and ImageJ 
software (National Institutes of Health) were used for image analysis. The 
infiltration rate in the ventral white matter of the mouse spinal cord was cal-
culated as the ratio in the number of DAPI+ nuclei between EAE mice and 
naive mice per unit of area. The number of CD4, CD19, F4/80, and APP-
positive cells was also calculated per unit of area. TrkB-T1 signal was quanti-
fied based on the number of TrkB-T1–positive pixels/mm2 (arbitrary unit). 
Colocalization between GFAP and TrkB-T1 was calculated using ImageJ 
(Colocalization plug-in) and expressed as the percentage of colocalized pixels/
total GFAP-positive pixels.
Astrocyte culture, stimulation, and analysis. Human primary fetal astro-
cytes (Aloisi et al., 1992) were maintained in culture in DME–high glucose 
medium (Celbio-Euroclone) supplemented with 200 mM l-glutamine 
(Celbio-Euroclone), 100 mM sodium pyruvate (Celbio-Euroclone), anti-
biotics (1% Pen-Strep solution; Celbio-Euroclone), and 10% FCS (PAA; 
MMedical). Mouse primary astrocytes were prepared from newborn mice as 
described in Aloisi et al. (1998). Purity of human and mouse astrocyte cul-
tures was checked by GFAP staining and was >95%. Treatment with 1–5–25 
ng/ml of human recombinant mature BDNF (PeproTech), 5 ng/ml NT-3 
(Abcam), 5 ng/ml NT-4 (Abcam), and 10 ng/ml IL-1 (R&D Systems) was 
nitrotyrosine signals were greatly reduced in the CNS of 
GFAP-cre:TrkBflox/flox EAE mice, indicating that TrkB 
signaling in astrocytes is crucial for NO synthesis in vivo. 
Thus, the decreased immune cell infiltration and neurode-
generation in the double transgenic EAE animals could be 
linked to the reduced NO production, considering that NO 
is a positive regulator of vascular permeability and forms neu-
rotoxic products. Interestingly, in MS lesions, areas with dif-
fuse nitrosylation were detected, and nitrosylated axons were 
surrounded by the TrkB-positive glial network.
In summary, our data indicate that the in vitro TrkB- 
dependent astrocyte response to neurotrophins may cause neu-
rodegeneration via NO release and that the abolition of this 
pathway in vivo confers resistance to neurodegeneration in-
duced by experimental neuroinflammation. NO triggers neu-
ronal death by altering energy metabolism (Brorson et al., 
1999), and mitochondrial dysfunction has been reported in MS 
lesions (Mahad et al., 2008). Thus, it may be speculated that in 
MS, the up-regulated expression of TrkB on astrocytes con-
tributes to the neuronal damage via NO production. Strategies 
to blockade this neurodegenerative pathway could lead to the 
development of a novel neuroprotective therapy for MS.
MATERIALS AND METHODS
Mice. Mice carrying loxP-flanked TrkB alleles (Luikart et al., 2005) were 
provided on a mixed background by L.F. Parada. Mice were backcrossed 
with wild-type C57BL/6N mice for seven generations before crossing with 
C57BL/6N hGFAP-cre transgenic mice (NCI-MMHCC) to obtain GFAP-
cre:TrkBflox/flox conditional mutant mice and control TrkBflox/flox lit-
termates. As reported, the GFAP-cre transgene mediates excision of LoxP-flanked 
sequences in GFAP-expressing cell lineages (Malatesta et al., 2003; Cai et al., 
2007), and transgenesis in the hGFAP promoter has been extensively used 
to assess functions of spinal cord astrocytes in adult animals (Brambilla et al., 
2005, 2009b). Because loxP sites flank both transcription initiation sites and 
the first coding exon of the TrkB gene, all TrkB isoforms are deleted. The 
GFAP-cre:TrkBflox/flox conditional mutant mice are viable and live to 
adulthood (Luikart et al., 2005).
EAE induction. EAE was induced in 8-wk-old female mice by subcuta-
neous injection of 200 µg MOG35–55 emulsified in complete Freund’s adju-
vant containing 5 mg/ml Mycobacterium tuberculosis (DIFCO). Bordetella pertussis 
toxin (List-Quadratech) was administered by intraperitoneal injection on 
the day of immunization (400 ng/mouse) and 2 d later (200 ng/mouse). Animals 
were monitored daily by measuring weight and examining disease scores as 
follows: 0 = no disease, 1 = flaccid tail, 2 = gait disturbance, 3 = complete 
hind limb paralysis, 4 = tetraparesis, and 5 = death. One experimenter 
was blind to mice genotypes. All procedures involving animals were au-
thorized by the Italian General Direction for Animal Health at the Ministry 
for Health.
Primary immune responses. Cells from spleens and draining lymph nodes 
(popliteal, inguinal, paraaortal, and axillar) of GFAP-cre:TrkBflox/flox and 
TrkBflox/flox mice were harvested at day 10 after immunization with 
MOG35–55 peptide. 2 × 105 cells/well were seeded in 96-well round-bottom 
plates in RPMI + 5% FCS and stimulated with increasing concentrations of 
MOG35–55 peptide. After 72 h of incubation (37°C, 5% CO2), cultures were 
pulsed for 18 h with 0.5 µCi/well of [3H]thymidine, and proliferation was 
measured from quintuplicate cultures on a  counter (PerkinElmer).
Human MS and control tissue samples. 12 brain samples from six fe-
male MS patients (aged 43–71 yr) and 14 from six female healthy controls 
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Treatment with anti-p75NTR or anti-BDNF blocking antibodies. 
Human astrocytes were exposed to serum-free medium supplemented with 
stimuli (25 ng/ml BDNF, 10 ng/ml IL1, or vehicle) in the presence of 
10 µg/ml anti–human p75NTR blocking monoclonal antibody (clone 
NGFR5; Invitrogen) or purified mouse IgG1 (BD). For BDNF blocking 
experiments, human astrocytes were exposed to serum-free medium added 
with stimuli (25 ng/ml BDNF, 10 ng/ml IL1, or vehicle) and 10 µg/ml 
anti–human BDNF polyclonal antibody (Millipore) or rabbit IgG (Jackson 
ImmunoResearch Laboratories, Inc.). Alternatively, neuronal cultures were 
exposed to ACM supplemented with BDNF blocking antibody or with the 
corresponding isotype control. For analysis, at least 1,800 nuclei/treatment 
were analyzed. All experiments included at least three technical replicates.
BDNF ELISA. BDNF levels were measured in human astrocyte superna-
tants with BDNF Emax ImmunoAssay System (Promega) according to the 
manufacturer’s protocol. Colorimetric read-out was analyzed by Epoch 
Micro-Volume Spectrophotometer System (Biotek).
Live imaging. Rat primary neurons were monitored during treatment with 
either recombinant BDNF or ACM (sNT, sBDNF, or sIL1) by time-lapse 
DIC (differential interference contrast) imaging (one stack every 5 min) 
using a fluorescence microscope (Eclipse TE 2000-e; Nikon) equipped with 
a Q-imaging Fast Camera (Rolera MGi plus) and a temperature/CO2 con-
centration control unit (OKOlab). Either 20× (NA 0.50) or 40× (NA 0.75) 
air objectives (Nikon) were used for live imaging acquisition. DAF-FM–
loaded astrocytes were monitored for NO production every 20 min starting 
from stimulation (time point 0). Both DIC and green fluorescence (excita-
tion wavelength: 488 nm, filter 450–490 nm; emission filter: 505 nm) images 
were acquired using a 20× air objective. Video analysis was performed using 
NIS Elements AR software version 3.0 (Nikon) and ImageJ software.
Nitrite/nitrate production by human astrocytes. To quantify the 
amount of nitrites and nitrates in astrocyte supernatants, a total nitrite/nitrate 
colorimetric assay kit (Cayman Chemical) was used according to the manu-
facturer’s protocol. Colorimetric read-out was analyzed via a Multiskan 
reader (Thermo Fisher Scientific).
Statistical analysis. Normality of the distribution was assessed by 
Kolmogorov–Smirnov statistics, and significance was measured by the Student’s 
t test with homeostatic variance in case of normal distribution or by Mann-
Whitney U test in case of non-normal distribution. For statistic evaluation of 
EAE clinical score, the nonparametric Mann-Whitney ranking U test was used. 
All p-values were two-sided and subjected to a significance level of 0.05.
Online supplemental material. Fig. S1 shows single frames of time-lapse 
imaging videos of neuronal cultures during treatment with ACM. Videos 
1–3 show time-lapse imaging of neuronal cultures during treatment with 
ACM from astrocytes exposed to vehicle, IL-1, or BDNF, respectively. 
Video 4 shows time-lapse imaging of neuronal cultures exposed to recom-
binant BDNF. Videos 5–7 show time-lapse imaging of human primary 
astrocytes loaded with DAF-FM and exposed to vehicle, BDNF, or IL-1, 
respectively. Online supplemental material is available at http://www.jem 
.org/cgi/content/full/jem.20110698/DC1.
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performed in serum-free medium. Supernatants were centrifuged (330 g, 
5 min, 4°C) to remove cell debris and stored at 20°C. If required, astro-
cytes were loaded with the NO dye DAF-FM (Invitrogen) and stimulated in 
phenol red–free DME (Invitrogen) medium. Loaded cells were either stimu-
lated during time-lapse imaging or treated for 1.5 h and then fixed in 4% PFA 
and DAPI-stained in PBS/0.2% Triton X-100. The number of NO-producing 
cells was calculated as the percentage of total DAPI-positive cells. At least 900 
cells/treatment were analyzed. If required, 10 µM L-NAME (Santa Cruz 
Biotechnology, Inc.), an NO inhibitor, was added together with stimuli.
RNA extraction, cDNA synthesis, and quantitative PCR. RNA from 
snap-frozen CNS tissue or from cultured astrocytes was extracted using Tri-
reagent (Invitrogen) according to the manufacturer’s instructions. cDNA 
was prepared using random hexamer primers and Superscript III reverse 
transcription (all from Invitrogen) according to the manufacturer’s instruc-
tions. Real-time PCR was performed using TaqMan Universal Master Mix 
on the Gene AMP 7500 PCR platform (Applied Biosystems). Messenger 
RNA levels of target genes were graphically reported as the percentage of 
the housekeeping gene Cyclophilin A (PPIA). The amplification sets for 
human TrkB isoforms were previously reported (Berzi et al., 2008). Ampli-
fication sets for human PPIA and mouse GAPDH, mouse TrkB, and mouse 
p75NTR were purchased from Applied Biosystems.
Cytofluorometry. Human primary astrocytes were stained with mouse 
–TrkB-ECD (clone 72509; R&D Systems) or isotype control (BD), followed 
by detection with Alexa Fluor 488–conjugated donkey -mouse secondary 
antibody (Invitrogen). p75NTR was stained with mouse -p75NTR PE 
conjugated (clone C40-1457; BD). Samples were analyzed using a FACS-
Calibur machine (BD).
Neuronal culture, stimulation, and analysis. Spinal primary mixed 
neurons were obtained from 16-d-old Sprague-Dawley rat embryos as 
described previously (Melli et al., 2006a,b). In brief, embryo spinal cords, 
depleted of spinal root ganglia, were dissected, carefully minced, and 
digested for 15 min at 37°C with 500 µg/ml DNAsi I (Roche) and 0.25% 
trypsin (Invitrogen) in L-15 medium (Invitrogen) supplemented with anti-
biotics. After digestion, the tissue homogenate was washed three times 
with L-15 medium and finally cultured in Neurobasal medium (Invitro-
gen) supplemented with 10 ng/ml of glial cell–derived neurotrophic factor 
GDNF (Sigma-Aldrich), 20 ng/ml fibroblast growth factor FGF (Pepro-
Tech), 5 µg/ml insulin (Sigma-Aldrich), B27 supplement (Invitrogen), 1% 
FCS, and 10 mM glucose. Cells were seeded on poly-lysine– and collagen 
(both from Sigma-Aldrich)-coated glass-inserted dishes (MatTek), on glass 
slides (Menzel), and/or on chamber slides (Nunc). After 24 h, 15 µM 
cytosine b-D-arabinofuranoside (AraC; Sigma-Aldrich) was added to cul-
tures and left for 4 d to eliminate contaminating microglia cells, astrocytes, 
and oligodendrocytes. After 1 d in AraC-free medium, neurons were 
exposed to ACM or recombinant factors for 24 h. Then they were fixed 
with 4% PFA, permeabilized with 0.2% Triton X-100 in PBS, and blocked 
with 3% BSA in PBS. Staining with 2 µg/ml of monoclonal antibody –-
tubulin (Tuj1; Covance) and detection with donkey -mouse-IgG Alexa 
Fluor 594 antibody were performed. Finally, the green fluorimetric TUNEL 
reaction (DeadEnd fluorimetric TUNEL kit; Promega) was performed to 
label apoptotic nuclei according to the manufacturer’s protocol, and all 
nuclei were stained with DAPI. Neuronal cultures were 100% pure, as all 
cells were -tubulin positive. Neuronal fragmentation was quantified as 
loss in -tubulin MFI compared with controls. The extent of apoptosis 
was quantified as the percentage of TUNEL-positive nuclei on all DAPI-
labeled nuclei. At least 2,700 nuclei/treatment were analyzed. If necessary, 
10 µM L-NAME was added together with ACM. Images were acquired 
using an Axiophot fluorescence microscope equipped with 10× (NA 0.30), 
20× (NA 0.50), and 40× (NA 0.75) air objectives or a CTR5500 fluores-
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